Is radiosurgery a neuromodulation therapy? : A 2009 Fabrikant award lecture - PubMed

Is radiosurgery a neuromodulation therapy? : A 2009 Fabrikant award lecture

Jean Régis et al. J Neurooncol. 2010 Jun.

Abstract

Radiosurgery is commonly considered to be effective through a destructive physical mechanism on neural tissue. Since its invention by Leksell in the 1950s, clinical and experimental experience of radiosurgery has demonstrated that for classical indications, for example arteriovenous malformations and benign tumors, radiosurgery is effective because of its specific histological effects of thrombotic endothelial proliferation and apoptosis, not simple coagulative necrosis. In functional neurosurgery, the strategy is either to target a small volume of normal tissue (i.e., ventrointermediate nucleus, capsulotomy, trigeminal neuralgia, etc.) with a high dose (80-140 Gy at maximum) or to target a large volume of tissue (i.e., 5-9 cc in epilepsy radiosurgery) with a moderate dose (17-24 Gy at the marginal isodose). These procedures have been proposed, technically performed, and evaluated on the basis of the hypothesis that their mechanism of action is purely destructive. However, modern neurophysiological, radiological and histological studies are leading us to question this assumption. Tissue destruction is turning out to be either absent or minimal and in almost all cases insufficient to explain the clinical effects obtained. Therefore, one possibility is that radiosurgery is inducing changes in the functioning of the neural tissue, by inducing remodeling of the glial environment, and is leading to the modulation of function while preserving basic processing. Thus, most radiosurgery procedures may induce the desired biological effect without requiring the histological destructive effect for completion of the therapeutic objective. Therefore the concept of "lesional" radiosurgery may be incorrect and a completely hidden world of neuromodulatory effects may remain to be discovered.

Similar articles

• Radiosurgery as neuromodulation therapy!

  Régis J. Régis J. Acta Neurochir Suppl. 2013;116:121-6. doi: 10.1007/978-3-7091-1376-9_19. Acta Neurochir Suppl. 2013. PMID: 23417469

• Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.

  Lunsford LD, Flickinger JC, Larson D. Lunsford LD, et al. Oncologist. 1997;2(1):59-61. Oncologist. 1997. PMID: 10388030

• [Neurosurgery using the Gamma Knife].

  Várady P, Dheerendra P, Nyáry I, Vajda J, Ladislau S. Várady P, et al. Orv Hetil. 1999 Feb 14;140(7):331-45. Orv Hetil. 1999. PMID: 10091503 Hungarian.

• Gamma Knife surgery, a neuromodulation therapy in epilepsy surgery!

  Régis J, Bartolomei F, Hayashi M, Chauvel P. Régis J, et al. Acta Neurochir Suppl. 2002;84:37-47. doi: 10.1007/978-3-7091-6117-3_4. Acta Neurochir Suppl. 2002. PMID: 12379003 Review.

• [Stereotaxic radiosurgery. Review of their indications and limitations].

  Vila Calveras F. Vila Calveras F. Neurologia. 2001 Feb;16(2):74-9. Neurologia. 2001. PMID: 11257933 Review. Spanish.

Cited by

• Gamma knife for functional diseases.

  Régis J. Régis J. Neurotherapeutics. 2014 Jul;11(3):583-92. doi: 10.1007/s13311-014-0276-z. Neurotherapeutics. 2014. PMID: 24906720 Free PMC article. Review. No abstract available.

• Neuromodulation via Focal Radiation: Radiomodulation Update.

  Schneider MB, Walcott B, Adler JR Jr. Schneider MB, et al. Cureus. 2021 Apr 26;13(4):e14700. doi: 10.7759/cureus.14700. Cureus. 2021. PMID: 33927960 Free PMC article. Review.

• Angiographic characteristics of epileptogenic arteriovenous malformations and effectiveness in the seizure control after treatment with radiosurgery.

  Cordero-Tous N, Jorques-Infante AM, Santos-Martin L, Alcazar-Romero PP, Fandiño-Benito E, Martin-Linares JM, Olivares-Granados G, Horcajadas-Almansa A. Cordero-Tous N, et al. J Radiosurg SBRT. 2014;3(2):103-110. J Radiosurg SBRT. 2014. PMID: 29296391 Free PMC article.

• High-precision stereotactic irradiation for focal drug-resistant epilepsy versus standard treatment: a randomized waitlist-controlled trial (the PRECISION trial).

  Zegers CML, Swinnen A, Roumen C, Hoffmann AL, Troost EGC, van Asch CJJ, Brandts L, Compter I, Dieleman EMT, Dijkstra JB, Granzier M, Hendriks M, Hofman P, Houben RMA, Ramaekers B, Ronner HE, Rouhl RPW, van der Salm S, Santegoeds RGC, Verhoeff JJ, Wagner GL, Zwemmer J, Schijns O, Colon AJ, Eekers DBP. Zegers CML, et al. Trials. 2024 May 21;25(1):334. doi: 10.1186/s13063-024-08168-9. Trials. 2024. PMID: 38773643 Free PMC article. Clinical Trial.

References

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer